On November 20, Hana Securities raised its target price for Alteogen from 550,000 won to 640,000 won, stating that the company is now positioned to rival large-cap pharmaceutical firms listed on KOSPI. The investment rating was maintained at 'Buy'.


Kim Seona, a researcher at Hana Securities, explained, "Previously, our valuation method only reflected estimated royalties in the corporate value. However, with the launch of Keytruda SC in the United States and Europe, it is now necessary to factor in product sales from commercialization." She added, "In addition, since the company plans to build a manufacturing plant with the goal of starting operations in 2028, depreciation expenses and other related costs must also be considered. This structure is similar to that of a pharmaceutical company, so we are changing our corporate value to cash generation (EV/EBITDA) estimation method." She continued, "For the 2025 EV/EBITDA peer group average, we applied a multiple of 37.8 times, referencing Samsung Biologics, Celltrion, SK Biopharmaceuticals, and Yuhan Corporation, which have a high proportion of global sales."


Hana Securities forecasts Alteogen's revenue for this year at 275.2 billion won and operating profit at 164.4 billion won. Kim estimated, "Product sales for Keytruda SC are projected to account for 5% of total Keytruda SC sales, and for ALT-B4 products in the pipeline other than Keytruda SC, we estimated sales based on the average of existing figures." She added, "Revenue estimates that are recognized in portions according to accounting standards, a milestone payment from Keytruda SC's European marketing approval (estimated at about 26.5 billion won), and commercialization sales of ALT-B4 for Keytruda SC are all expected to be reflected in the fourth quarter this year."


Additional technology licensing-out (L/O) deals are also anticipated within the year. Kim stated, "We still maintain expectations that more than two L/O deals could occur within this year."



Alteogen will hold an extraordinary general meeting of shareholders on December 8 and will begin the full-fledged process for transferring its listing to the Korea Exchange main board. Kim noted, "With the revenue and operating profit confirmed in the third quarter, the company has already achieved an operating margin of 54.4%. With the simultaneous full-scale launch of Keytruda SC in the United States and Europe, the company is expected to continue receiving stable royalties in the next quarter and next year, so there appears to be no risk of the operating margin dropping below 50% and profits declining." She added, "The patent for ALT-B4 is valid until 2039, leaving ample time for monetization based on ALT-B4 alone. Therefore, we assess that Alteogen has secured a position and conditions comparable to those of large-cap pharmaceutical companies listed on KOSPI."

[Click e-Stock] "Alteogen Now on Par with Major KOSPI Pharma Firms... Target Price Raised" View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing